Liraglutide 3 mg per day Shows Efficacy in Weight Loss for Individuals with Bipolar Disorder: Study

• The primary outcome measure was the percent change in body weight from baseline to the end of the study.

• Secondary outcomes included the percentage of participants who lost ≥5% of baseline body weight and changes in metabolic variables and measures of eating psychopathology.

• Compared to placebo, liraglutide recipients experienced significantly greater reductions in body weight, BMI, hemoglobin A1c levels, binge eating, and hunger.

• Liraglutide was well tolerated, with no significant differences in baseline characteristics between the liraglutide and placebo groups.

The study findings suggest that liraglutide 3 mg/d may be an effective and safe option for weight loss in individuals with stable BD who are obese or overweight. This medication could potentially address the significant health risks associated with obesity in this population.

Reference:

McElroy, S. L., Guerdjikova, A. I., Blom, T. J., Mori, N., & Romo-Nava, F. Liraglutide in obese or overweight individuals with stable bipolar disorder. Journal of Clinical Psychopharmacology,2024;44(2):89–95. https://doi.org/10.1097/jcp.0000000000001803